Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 7/20 | 0.45 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747519 | 0.99 | VDR (0.43) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747496 | 0.97 | VDR (0.45) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747533 | 0.97 | VDR (0.45) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747380 | 0.95 | VDR (0.44) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747497 | 0.91 | VDR (0.42) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747508 | 0.90 | VDR (0.41) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747383 | 0.89 | VDR (0.45) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL16747398 | 0.89 | VDR (0.38) | VDRCYP24A1 | |
| SCHEMBL16747388 | 0.88 | VDR (0.44) | VDRCYP24A1PPARAPPARGSPHK2 | |
| SCHEMBL18134429 | 0.86 | VDR (0.49) | VDRCYP24A1PPARAPPARGSPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072873-B1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIV SANTIAGO COMPOSTELA (ES) | 2019-02-20 | — | — | EP | disclosed |
| US-9663429-B2 | Vitamin D analogues of pharmaceutical interest | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2016-10-13 | — | — | US | disclosed |
| EP-3072873-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | Universidade De Santiago De Compostela (ES) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015075291-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | CYP24A1, VDR, CYP2R1 | VDR 2/4885CYP24A1 1/4885PPARA 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.